Also known as: AGI-1067; Probucol monosuccinate
Succinobucol (AGI-1067) is a metabolite and derivative of probucol with antioxidant and anti-inflammatory properties. It has been investigated for cardiovascular protection, particularly in atherosclerosis and acute coronary syndrome. Mediocon Inc supplies pharmaceutical-grade Succinobucol conforming to IP / BP / EP / USP specifications.
As a potent antioxidant, Succinobucol inhibits LDL oxidation and reduces vascular inflammation. It has been studied in clinical trials for its cardioprotective effects.
Key Features
Applications
Why Choose Mediocon
| Parameter | Specification |
|---|---|
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Mfg Date | MAR 2025 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Succinobucol (CAS 216167-82-7) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Succinobucol is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance